Clinical trial

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

NCT02404506

Study summary

ClinicalTrials.gov

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Eribulin mesilate Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2015-08-17

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Adenocarcinomaverified · MONDO: adenocarcinoma

Interventions

Eribulin mesilateDRUG

Sponsors & collaborators

Swiss Cancer Institutelead sponsor

Mapped research locations

Sankt GallenSwitzerland3 ZurichSwitzerland2 BaselSwitzerland2 BernSwitzerland2 LausanneSwitzerland1 LuganoSwitzerland1 ChurSwitzerland1 AarauSwitzerland1 BellinzonaSwitzerland1 WinterthurSwitzerland1 BadenSwitzerland1 FribourgSwitzerland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02404506 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.